Sargent Investment Group LLC Takes Position in Insulet Co. (NASDAQ:PODD)

Sargent Investment Group LLC acquired a new stake in Insulet Co. (NASDAQ:PODD) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 955 shares of the medical instruments supplier’s stock, valued at approximately $256,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PODD. Creative Planning grew its holdings in Insulet by 35.0% during the second quarter. Creative Planning now owns 7,430 shares of the medical instruments supplier’s stock worth $1,499,000 after acquiring an additional 1,928 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in Insulet by 10.5% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,000 shares of the medical instruments supplier’s stock worth $202,000 after acquiring an additional 95 shares during the period. Sanctuary Advisors LLC acquired a new stake in Insulet during the second quarter worth about $830,000. Handelsbanken Fonder AB grew its holdings in Insulet by 5.5% during the third quarter. Handelsbanken Fonder AB now owns 17,216 shares of the medical instruments supplier’s stock worth $4,007,000 after acquiring an additional 900 shares during the period. Finally, Czech National Bank grew its holdings in Insulet by 7.0% during the third quarter. Czech National Bank now owns 14,283 shares of the medical instruments supplier’s stock worth $3,324,000 after acquiring an additional 937 shares during the period.

Insulet Stock Performance

NASDAQ PODD opened at $284.70 on Thursday. The company has a market cap of $19.97 billion, a PE ratio of 48.75, a price-to-earnings-growth ratio of 3.49 and a beta of 1.23. The stock’s 50 day simple moving average is $269.53 and its 200-day simple moving average is $239.99. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $287.00. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. Insulet had a return on equity of 27.98% and a net margin of 21.22%. The firm had revenue of $543.90 million for the quarter, compared to the consensus estimate of $518.50 million. During the same quarter last year, the business posted $0.71 earnings per share. As a group, equities research analysts anticipate that Insulet Co. will post 3.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on PODD shares. TD Cowen raised their target price on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Wells Fargo & Company increased their price target on Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Morgan Stanley increased their price target on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Sanford C. Bernstein assumed coverage on Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target on the stock. Finally, Canaccord Genuity Group increased their price target on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $277.13.

Insider Buying and Selling

In related news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by company insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.